Second Contaminant Found in Torrent Pharmaceuticals Recalled Valsartan

Published on Friday, September 14, 2018 by Staff

Second Contaminant Found in Torrent Pharmaceuticals Recalled Valsartan

The FDA announced that it has detected an additional contaminant in three lots of Torrent Pharmaceuticals recalled valsartan drugs. N-Nitrosodiethylamine (NDEA), a known animal and human carcinogen, was found in Torrent’s valsartan 160mg (Lot BV47D001) and 320mg (Lots BV48D001 and BV48D002). These tablets were produced using valsartan API, manufactured by Zhejiang Huahai Pharmaceuticals (ZHP) – also found to contain NDEA.

According to the FDA, “like NDMA [the first contaminant found in valsartan drugs], NDEA is also formed from a specific sequence of manufacturing steps and chemical reactions.” Manufacturers should continue to test their products for these contaminants. The FDA will post a testing method for the detection of NDEA that can be used by manufacturers.

Lastly, “The FDA reminds patients taking valsartan from a recalled lot to continue taking their current medicine until their doctor or pharmacist provides a replacement or a different treatment option. Any patient who is taking valsartan from a recalled lot who has not yet spoken to their pharmacist or doctor should do so promptly.”

FDA Press Announcement dated Septmber 13, 2018 https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620499.htm

FREE VALSARTAN
CASE EVALUATION

Please fill in the form to request a FREE case evaluation from one of our attorneys if you or a loved one have taken Valsartan after January 1st of 2015 and subsequently been diagnosed with stomach cancer, small intestine cancer, colorectal cancer, esophageal cancer, liver cancer, prostate cancer, pancreatic cancer, leukemia, non-Hodgkin’s lymphoma, or multiple myeloma after January 1st of 2017.

*
*
*
*
*
Have you or someone you know taken Valsartan after January 1st of 2015 and subsequently been diagnosed with cancer after January 1st of 2017? *
 All personal information will be kept private. Please read our disclaimer.